Company: BIAF
Filing Date: 2025-04-29
Form Type: 10-K/A
Source: 0001641172-25-006707
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-29
Form: 10-K/A
Chunk 2
---
 shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of June 28, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of a share of the registrant’s common stock on that date, as reported by the Nasdaq Capital Market on such date was approximately $ 22.6million. Shares of the registrant’s common stock held by each executive officer, director and holder of 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.

The number of shares outstanding of the issuer’s common stock, $ 0.007par value (the “Common Stock”), is 18,255,824as of March 31, 2025.

<div align='center'>DOCUMENTS INCORPORATED BY REFERENCE

None.</div>

<div align='center'>TABLE OF CONTENTS</div>

|            |                                                                                                | Page |
| PART III   |                                                                                                |      |
| Item       
 10.        | Directors, Executive Officers and Corporate Governance                                         |    4 |
| Item       
 11.        | Executive Compensation                                                                         |    9 |
| Item       
 12.        | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |   14 |
| Item       
 13.        | Certain Relationships and Related Transactions, and Director Independence                      |   16 |
| Item       
 14.        | Principal Accountant Fees and Services                                                         |   18 |
| PART IV    |                                                                                                |      |
| Item       
 15.        | Exhibit and Financial Statement Schedules                                                      |   20 |
| Signatures |                                                                                                |   25 |

| 2 |

<div align='center'>EXPLANATORY NOTE</div>

bioAffinity Technologies, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025 (the “Original Filing”).

This Amendment is being